ESCALATED BEACOPP X 2 + ABVD X 4 IS SUPERIOR TO ABVD X 6 IN ADVANCE STAGE CLASSICAL HODGKIN LYMPHOMA: EXPERIENCE IN A TERTIARY CENTER

Introduction: Classical Hodgkin lymphoma (cHL) is a curable disease but results in advanced stages are suboptimal when treated with standard treatment ABVD 10%–15% of primary refractoriness and 30% relapses, although 5 years overall survival (OS) around 88%–90%. First-line more intensive schemes such as escalated BEACOPP has improved progression-free (PFS) these patients, associating greater toxicity. However, did not improve OS compared to due the efficacy rescue treatments, assuming high toxic cost. We present our experience optimize first-line cHL. Methods: retrospectively analyzed patients stage cHL (IIB-IV) curative intent center between December 2008 2022 (Table 1). In period 2008–2011, were x 6. During 2011–2022, we implemented strategy intermediate PET guided (PET2) after (x 2). With PET2 negative, continued ABVD/AVD 4; positive 4. Both groups received radiotherapy on bulky masses. evaluate this by comparing toxicity two study periods. Results: 2008–11 period, 21 during 2011–22 60 intensified one (S). PET2, 55 (91.6%) group achieved CR (8.4%) PR versus (23.8%) CR, 14 (66.7%) 2 (9.52%) refractory group. At end treatment, 58 (96.6%) 15 (71.4%) There where 4 (19%) (3.3%) PFS for was 90.8% at 57.1% (p = 0.00025). 98.1% 85.7% 0.01). The incidence admissions febrile neutropenia tended be higher (15% vs. 4.76%, p 0.44) no significant differences observed secondary malignancies or infertility. deaths any Keywords: Hodkin lymphoma, PET-CT No conflicts interests pertinent abstract.